
Epalrestat
CAS No. 82159-09-9
Epalrestat ( ONO-2235 )
产品货号. M16054 CAS No. 82159-09-9
一种非竞争性可逆醛糖还原酶抑制剂,对来自大鼠晶状体和人胎盘的纯化醛糖还原酶的 IC50 分别为 10 nM 和 26 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
10MG | ¥373 | 有现货 |
![]() ![]() |
25MG | ¥543 | 有现货 |
![]() ![]() |
50MG | ¥721 | 有现货 |
![]() ![]() |
100MG | ¥1166 | 有现货 |
![]() ![]() |
200MG | ¥1766 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Epalrestat
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种非竞争性可逆醛糖还原酶抑制剂,对来自大鼠晶状体和人胎盘的纯化醛糖还原酶的 IC50 分别为 10 nM 和 26 nM。
-
产品描述A noncompetitive and reversible aldose reductase inhibitor with IC50 of 10 nM and 26 nM for purified aldose reductase from rat lens and human placenta, respectively; used for the treatment of diabetic neuropathy.Diabetes Approved.
-
体外实验RT-PCR Cell Line:rat SCs Concentration:10 or 50 μM Incubation Time:4 h Result:Increased the nuclear level of active Nrf2 by 1.8- and 3.8-fold at 10 and 50 μM, and failed to increase Nrf2 mRNA levels.
-
体内实验Animal Model:db/db mice Dosage:0.08% (w/w) in fed regular chow Administration:8 weeks Result:Ameliorated GBM thickening and mesangial matrix deposition in kidney tissue.Reduced the elevated sorbitol and fructose in the plasma, urine, and renal cortex of db/db mice.Reduced myo-inositol in the plasma and urine, whereas increased myo-inositol in the renal cortex.Animal Model:Rats were treated with high-fat and high-sugar diet for 4 weeks, and injected with Streptozotocin at 4 and 8 weeks Dosage:100 mg/kg/d Administration:i.g. 6 weeks Result:Improved pathological structures of neurites and myelin.Increased SOD, CAT and GPX protein levels in sciatic nerves.Decrease aldose reductase level in sciatic nerves.
-
同义词ONO-2235
-
通路Metabolic Enzyme/Protease
-
靶点Aldose Reductase
-
受体Aldosereductase
-
研究领域Metabolic Disease
-
适应症Diabetes
化学信息
-
CAS Number82159-09-9
-
分子量319.3986
-
分子式C15H13NO3S2
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 3.1 mg/mL
-
SMILESO=C(O)CN(C/1=O)C(SC1=C/C(C)=C/C2=CC=CC=C2)=S
-
化学全称3-Thiazolidineacetic acid, 5-[(2E)-2-methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-, (5Z)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Yasuda H, et al. Diabetes. 1989 Jul;38(7):832-8.
2. Terashima H, et al. J Pharmacol Exp Ther. 1984 Apr;229(1):226-30.
3. Hotta N, et al. Diabet Med. 2012 Dec;29(12):1529-33.